MedTrace Logo

Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.

NCT07029230 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2025-11-17

No results posted yet for this study

Summary

Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.

Conditions

  • Congenital Heart Surgery
  • Congenital Heart Disease in Children
  • Fontan Physiology

Sponsors & Collaborators

  • University Children's Hospital, Zurich

    collaborator OTHER

  • Martin Schweiger

    lead OTHER

Principal Investigators

  • Martin Schweiger, Prof, MD, MBA · University Children's Hospital, Zurich

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2027-12-31
Completion
2029-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029230 on ClinicalTrials.gov